Variation IGFBP7 Markers and TIMP2 Induced by Injection of Contrast Iodized Drug at the Intensive Care Patient

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02881710

Acronym

ContraCHECK

Enrollment

Registered

2016-08-29

Start date

2014-04-09

Completion date

2016-03-27

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency

Brief summary

Multicenter, prospective, uncontrolled study to evaluate variations in urinary concentrations of TIMP-2 and PCI IGFBP7 induced injection during a CT scan in intensive care patient.

Interventions

OTHERcontrast product used to assess biomarkers variations

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients aged 18 years or more, * Hospitalized in intensive care, * Holders of a urinary catheter * Patient receiving a first CT with intravenous injection of PCI during their ICU stay. * Patient agreeing to participate in the research protocol

Exclusion criteria

* Anuria * Need to retain urine, whatever the reason (eg measurement of 24-hour proteinuria). * Urine unanalyzable whatever reason (eg urinary washing with double current probe, injection is saline to measure bladder pressure.). * Patient subjected to renal replacement * Patient already included in the study for a previous injection of PCI in intensive care.

Design outcomes

Primary

Measure	Time frame
significant increase in urinary concentrations of TIMP-2 and IGFBP7 defined as an increase of NephroCheck® test of more than 0.2 [ng / mL] 2/1000) after PCI injection	follow up: 5 days after injection

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026